We are live on ! Find out more
BSX.PRA

Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A

Delisted

BSX.PRA was delisted on the 31st of May, 2023.

1 hedge funds and large institutions have $32.4K invested in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% less funds holding

Funds holding: 561 (-55)

100% less capital invested

Capital invested by funds: $1.15B → $32.4K (-$1.15B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 55

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-55
Holders Change %
-98.21%
% of All Funds
0.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
1
Closed
55
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SC
26
Sculptor Capital
New York
-$7.48M -61,765 Closed
Citigroup
27
Citigroup
New York
-$5.75M -47,500 Closed
ClearBridge Investments
28
ClearBridge Investments
New York
-$3.89M -32,118 Closed
TD Asset Management
29
TD Asset Management
Ontario, Canada
-$3.63M -30,000 Closed
EDRH
30
Edmond de Rothschild Holding
Switzerland
-$3.47M -28,785 Closed
AM
31
AGF Management
Ontario, Canada
-$3.03M -25,000 Closed
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
-$3.03M -25,000 Closed
PCM
33
Palisade Capital Management
New Jersey
-$2.67M -22,150 Closed
CS
34
Credit Suisse
Switzerland
-$2.42M -20,000 Closed
RA
35
Rational Advisors
New York
-$2.28M -18,935 Closed
Jennison Associates
36
Jennison Associates
New York
-$1.16M -9,616 Closed
Wells Fargo
37
Wells Fargo
California
-$775K -6,400 Closed
Canada Life
38
Canada Life
Manitoba, Canada
-$631K -5,600 Closed
RJFSA
39
Raymond James Financial Services Advisors
Florida
-$578K -4,773 Closed
CWM
40
Calamos Wealth Management
Illinois
-$553K -4,570 Closed
CCM
41
Chicago Capital Management
Illinois
-$522K -4,312 Closed
American Century Companies
42
American Century Companies
Missouri
-$450K -3,728 Closed
CIC
43
Chase Investment Counsel
Virginia
-$441K -3,663 Closed
MSL
44
Mackay Shields LLC
New York
-$411K -3,400 Closed
VNA
45
Valley National Advisers
Pennsylvania
-$371K -3,000 Closed
FHB
46
First Hawaiian Bank
Hawaii
-$294K -2,430 Closed
Morgan Stanley
47
Morgan Stanley
New York
-$272K -2,244 Closed
Artisan Partners
48
Artisan Partners
Wisconsin
-$184K -1,521 Closed
Barclays
49
Barclays
United Kingdom
-$103K -848 Closed
Lazard Asset Management
50
Lazard Asset Management
New York
-$78K -648 Closed

BSX.PRA Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) for Q2 2023, worth a combined $32.4K — down 100% from $1.15B a quarter earlier.

Sellers outnumbered buyers: 55 funds closed out of BSX.PRA and 0 opened new positions — a net loss of 55 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was VOYA Investment Management, exiting entirely with an estimated $257M sold.

  • 1 institutional investor held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) as of Q2 2023, down from 56 in Q1 2023.
  • Funds reported $32.4K of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A positions in Q2 2023 and 55 closed out, a net change of -55 holders.
  • The largest Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A seller in Q2 2023 was VOYA Investment Management, an estimated $257M sold.

Based on aggregated 13F filings for Q2 2023.